the results of
the current on-treatment analysis reinforce that it is reasonable to
offer catheter ablation asfirst-line therapy to selected patients with
highly symptomatic paroxysmal AF. However, due to frequent need
for reablation and the risk of RFA related serious adverse events the
selection of initial treatment strategy should be based on open discussion
of the risks and benefits of the therapeutic options with the patient